Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "emerging-markets"

160 News Found

Glenmark Life Sciences IPO to open on July 27, 2021
News | July 26, 2021

Glenmark Life Sciences IPO to open on July 27, 2021

The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration


Cipla receives final approval for generic version of Brovana
News | June 24, 2021

Cipla receives final approval for generic version of Brovana

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana


Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
News | May 27, 2021

Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21

Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21


Sun Pharma Q4 FY21 net profit up 124%
News | May 27, 2021

Sun Pharma Q4 FY21 net profit up 124%

The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year


Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.


Aurore to merge with Solara in an all-stock transaction
News | April 10, 2021

Aurore to merge with Solara in an all-stock transaction

The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions


Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
News | February 15, 2021

Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr

The jump in profit is due to the better performance of the API business.


Biocon Biologics to offer its oncology biosimilars in 30+ countries
Biotech | February 05, 2021

Biocon Biologics to offer its oncology biosimilars in 30+ countries

The partnership is a significant step in delivering advanced cancer therapies to patients.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


Zydus eyes $6 bn market with strong COVID-19 portfolio
News | January 18, 2021

Zydus eyes $6 bn market with strong COVID-19 portfolio

With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential